BNTX

BioNTech SE

84.87 USD
+1.73 (+2.08%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

BioNTech SE stock is up 0.58% since 30 days ago. The next earnings date is Aug 5, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 100% of the previous 4 July’s closed higher than June. In the last 10 Unusual Options Trades, there were 6 CALLs, 4 PUTs. 100% of analysts rate it a buy.

Options Flow Last 10
Date & Time Expiration Date Strike Price Trade Type Size Open Interest
11 Jul 14:56 16 Aug, 2024 85.00 CALL 1395 93
11 Jul 14:58 16 Aug, 2024 87.50 CALL 1395 2492
12 Jul 18:29 20 Sep, 2024 95.00 CALL 300 206
12 Jul 19:00 17 Jan, 2025 110.00 PUT 11 36
12 Jul 19:01 20 Dec, 2024 110.00 PUT 13 0
17 Jul 18:29 16 Aug, 2024 85.00 CALL 146 1805
18 Jul 18:35 16 Aug, 2024 87.50 PUT 181 18
18 Jul 18:49 19 Jul, 2024 105.00 PUT 18 249
22 Jul 16:55 20 Sep, 2024 87.50 CALL 186 84
23 Jul 19:27 20 Sep, 2024 90.00 CALL 69 1053

About BioNTech SE

BioNTech SE develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma. It also develops neoantigen specific immunotherapy, such as Autogene cevumeran (BNT122) and BNT141.